453 419

Cited 0 times in

Chromosomal Abnormalities at 11q23 after Topoisomerase Ⅱ Inhibitor Treatment : A Report of Three Cases

Other Titles
 DNA Topoisomerase II 억제제 치료 후 발생한 11q23 재배열 
Authors
 우희연  ;  이경아  ;  성기웅  ;  ∙이홍기  ;  김선희 
Citation
 Korean Journal of Clinical Pathology (대한임상병리학회지), Vol.22(1) : 57-62, 2002 
Journal Title
Korean Journal of Clinical Pathology(대한임상병리학회지)
ISSN
 1598-6535 
Issue Date
2002
Keywords
Topoisomerase II inhibitors ; Secondary hematologic malignancy ; MLL gene
Abstract
Background :It has become apparent that the MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene is frequently rearranged in patients with secondary leukemia or myelodysplasia associated with chemotherapeutic regimens including topoisomerase II inhibitors (topo II inhibitors). Few studies have been reported on hematological or chromosomal abnormalities associated with topo II inhibitor therapy in Korea. We report three cases with topo II inhibitor therapy-related 11q23 abnormalities. First, a 10-year old female with a therapy-related chromosomal abnormality t(11;16) (q23;p13.3) without bone marrow abnormalities; second, a 67-year old male with therapy-related myelodysplastic syndrome (MDS) with add(11)(q23) and advanced to acute myeloid leukemia with t(2;11)(p23;q23) within a year; and third, a 42-year old male with therapy-related acute myeloid leukemia (AML) with 11q23 abnormality demonstrated by fluorescence in situ hybridization (FISH) analysis using a MLL gene probe and which later proved to be t(9;11)(p22;q23). The chemotherapeutic agents for the primary malignancies (ovarian primitive neuroectodermal tumor, PNET; squamous lung cell carcinoma; and Ewing`s sarcoma/PNET, respectively) consisted of topo II inhibitiors as well as alkylating agents. The latent periods from primary therapy to identification of 11q23 abnormalities were relatively short at 9 months, 35 months, and 22 months, respectively. Patients treated with topo II inhibitors are at risk for developing secondary MDS or leukemia that has distinct features from those associated with alkylating agents. The genetic basis and optimal treatment for clonal changes from topo II inhibitor therapy remain to be determined. A close follow-up of cytogenetic and/or FISH study with a MLL gene probe for patients with a history of topo II inhibitor treatment would be very useful for diagnosis and prediction of secondary hematologic malignancies.
Files in This Item:
T200208941.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Lee, Kyung A(이경아) ORCID logo https://orcid.org/0000-0001-5320-6705
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/144310
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links